- English (USA)
- English (UK)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Neuropace Inc (NPCE)
The Neuropace share price today is 15.26, view NASDAQ NPCE stock exchange data. Track the latest Neuropace share price with real-time updates on NPCE stock performance including market cap, day range, 52-week range and dividend yield. Access NPCE charts, earnings dates and analyst estimates to support your investment decisions.
15.35
-0.44(-2.79%)
Real-time Data·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
15.23
15.68
52 wk Range
7.56
19.60
NPCE is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
15.2315.68
52 wk Range
7.5619.60
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
NPCE Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Strong Buy
Price Target
19.88
Upside
+29.48%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Stock price movements are quite volatile
- Form DEF 14A NEUROPACE For: 21 April
- Investing.com
- Form DEF 14A NEUROPACE For: 21 April
- Investing.com
- Form 4 Neuropace Inc For: 5 March
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Analyst Ratings
8 Buy
0 Hold
0 Sell
Ratings:
8 analysts
Overall Consensus
Strong Buy
Analysts 12-Month Price Target:
Average 19.88
(+29.48% Upside)
Neuropace Inc SWOT Analysis
Innovative Epilepsy Tech | NeuroPace's RNS System revolutionizes treatment for drug-resistant focal epilepsy, showcasing strong clinical efficacy and market potential |
Financial Momentum | NeuroPace reports impressive revenue growth, with 2025 projections between $93-97 million, reflecting a 16-21% year-over-year increase |
Expanding Horizons | Explore NeuroPace's strategic initiatives, including Project CARE and potential new indications, which could double its addressable market |
Market Valuation | Analyst price targets range from $15 to $20 per share, indicating significant upside potential despite current trading above Fair Value |
Neuropace Inc Earnings Call Summary for Q1/2026
- Q1 2026 revenue rose 8% YoY to $22.1M, exceeding forecast of $21.65M; EPS of -$0.20 beat estimates by 9.09%, driven by RNS System sales growth.
- Stock remained stable at $15.70 with 0.19% after-hours gain despite earnings beat; analysts maintain strong buy rating with $18-$22 price targets.
- Operating expenses grew 10% to $21.5M, half the pace of revenue growth; non-GAAP gross margin reached 82.5%, improving operational leverage.
- Cash position declined to $54.8M from $61.2M due to typical Q1 outflows; company expects continued revenue growth and EPS improvements ahead.
- ECoG Assistant tool approval anticipated in Q2 2026; management cites supply chain risks, regulatory changes, and intense competition as key challenges.
Last Updated: 13-05-2026, 03:38 am
Read Full TranscriptEarnings
Latest Release
12-05-2026
EPS / Forecast
-0.20 / -0.22
Revenue / Forecast
22.1M / 21.65M
Compare NPCE to Peers and Sector
Metrics to compare | NPCE | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipNPCEPeersSector | |
|---|---|---|---|---|
P/E Ratio | −25.1x | −3.6x | −0.5x | |
PEG Ratio | −0.97 | −0.18 | 0.00 | |
Price/Book | 28.3x | 3.7x | 2.6x | |
Price / LTM Sales | 5.4x | 2.2x | 3.2x | |
Upside (Analyst Target) | 10.4% | 47.5% | 50.4% | |
Fair Value Upside | Unlock | 25.6% | 7.2% | Unlock |
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet which is used for prescribing and managing clinicians for programming implanted devices and managing patient care; and patient data management system, a secure online database that collects data that have been recorded by the RNS System; and nSight Platform, which provide clinicians with personalized patient reports, as well as programming suggestions. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Ownership
Ownership Overview
Top Holders
FAQ
What Is the Neuropace (NPCE) Share Price Today?
The Neuropace share price today is 15.35.
What is the current Neuropace (NPCE) share price and day range?
As of 15-05-2026, the Neuropace share price is 15.35, with a previous close of 15.79. The share price has ranged from 15.23 to 15.68 today, while the 52-week range spans from 7.56 to 19.60.
What Is the Neuropace Market Cap?
As of today, Neuropace market cap is 520.27M.
What Is the Neuropace (NPCE) Share Price Target?
The average 12-month share price target for Neuropace is 19.88, with a high estimate of 22 and a low estimate of 18. 8 analysts recommend buying, while 0 suggest selling, with an overall rating of Strong Buy and +29.48% Upside potential.
What Is Neuropace's Earnings Per Share (TTM)?
The Neuropace EPS (TTM) is -0.65.
When Is the Next Neuropace Earnings Date?
Neuropace will release its next earnings report on 06-08-2026.
From a Technical Analysis Perspective, Is NPCE a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
What Stock Exchange Does Neuropace Trade On?
Neuropace is listed and trades on the Nasdaq Stock Exchange.
What Is the Stock Symbol for Neuropace?
The stock symbol for Neuropace is "NPCE."
How Many Times Has Neuropace Stock Split?
Neuropace has split 0 times.
How Many Employees Does Neuropace Have?
Neuropace has 220 employees.
What Is the NPCE After Hours Price?
NPCE's last after hours stock price is 15.83, the stock has changed by 0.04, or 0.25%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.